Strong Q1 2026 sales growth, marking a solid start to the year

We have delivered a strong start to 2026, reporting total sales growth of 22.6% at constant exchange rates in the first quarter. The performance reflects solid execution across our core therapeutic areas and continued demand for our differentiated medicines.

The Q1 results underscore our focus on delivering meaningful innovation for patients while driving sustainable, long‑term growth.

Consistent growth across all core therapeutic areas

Our first‑quarter performance was supported by balanced growth across Oncology, Rare Disease, and Neuroscience, driven by the strength and diversification of our portfolio.

• Oncology sales increased by 13.0%, with by continued strong demand across key brands and markets.
• Rare Disease recorded exceptional growth of 125.4%, reflecting successful commercialization efforts and increasing patient access to Ipsen’s rare disease treatments.
• Neuroscience sales grew by 18.5%, supported by sustained underlying demand and effective commercial execution.

This performance demonstrates our ability to deliver growth across multiple therapeutic areas addressing high unmet medical needs.

Well positioned for the year ahead

We’re starting 2026 with momentum and confirmed our 2026 full-year guidance. Looking ahead, we remain focused on advancing our pipeline, supporting launches, and reinforcing our position in Oncology, Rare Disease, and Neuroscience.

* All figures at constant exchange rates.